UK’s CMA Investigates Essential Pharma Over Lithium
As An Interim Measure, Company Will Not Halt The Supply Of Priadel
The CMA has launched an investigation into Essential Pharma regarding its lithium-based treatment, Priadel. As an interim measure, the company has been advised to continue supplying the bipolar disorder treatment to UK patients.
You may also be interested in...
India’s Shilpa Medicare has received a warning letter from the US FDA for its finished dosage formulation facility in Jadcherla, Telangana. The company has insisted that supplies from the facility will not be disrupted while it engages with the FDA to resolve the issues.
After making several targeted investments aimed at enhancing its global production network, Siegfried has announced the acquisition of two manufacturing sites from Novartis in Spain. With this acquisition, the Swiss contract development and manufacturing organization is looking to create opportunities for profitable growth and achieve “critical size.”
Akorn aims for “long-term growth and a brighter future” after exiting Chapter 11 protection that it had filed for in May 2020. After completing the sale to its lenders, the company is now operating as a private entity under the legal name, Akorn Operating Company LLC.